MINISYMPOSIUM

Metabolic Rewiring in Cancer and Degenerative Diseases: From Intervention to Insight

Join us for a high-level scientific minisymposium bringing together leading international and Finnish experts at the intersection of drug discovery, metabolism, cancer biology, neurobiology, and translational medicine, featuring an exceptional lineup of speakers. The program will cover metabolic rewiring, cancer vulnerabilities, mitochondrial biology, NAD metabolism, neurodegeneration, therapeutic targeting, and emerging opportunities in drug discovery.

Speakers: Charles Brenner, Adam Renslo (UCSF), Andrei Goga (UCSF), Mart Saarma, Pirjo Laakkonen, Mikko Airavaara, Eija Pirinen, Vivek Sharma, Alexander Mühleip, Melissa Junttila (ORIC Pharma, USA) and Juha Klefström. 

A special highlight will be the expert panel: “Why Metabolism Matters – How New Insights into Metabolism will Advance Our Understanding of Biological Mechanisms and Disease Interventions”

For Students & PhD researchers 0.5 ECTS for symposium attendance + an additional 0.5 ECTS for poster presentation.

Three outstanding poster abstracts will be selected for short oral presentations, with awards for Best Talk and Best Poster.

This is an excellent opportunity to present your research, interact with leading scientists, gain new perspectives, and build collaborations.

Register now – seats are limited – and be part of the conversation shaping the future of metabolic biology, drug discovery, and therapeutic innovation.

👉 Register Here

The Helsinki Academic Drug Discovery Collaborative (HADDC) is a multidisciplinary cross-faculty collaborative at the University of Helsinki, which connects researchers across disciplines to advance innovative science in chemical biology and to accelerate discovery to therapeutic impact.